Norton Rose Fulbright represents Alaunos Therapeutics in preferred stock issuance

Global law firm Norton Rose Fulbright represented Alaunos Therapeutics (NASDAQ: TCRT) (Alaunos) in the private placement of series A-1 convertible preferred stock to a single institutional investor at a purchase price of US$1,000 per share.

The transaction closed on April 11, 2025. Alaunos plans to use the funding for general corporate purposes.

Alaunos is a clinical stage cellular immuno-oncology company focused on treating solid tumors through adoptive TCR-T cell therapy. Based in Houston, Texas, Alaunos engineers cell therapies that target Neoantigens arising from genomic mutations. Its proprietary solutions deliver tumor-specific killer T cells to cancer patient populations with unmet clinical need.